Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/21/2018 |
| Start Date: | October 15, 2018 |
| End Date: | October 15, 2025 |
| Contact: | Kerry Hepler |
| Email: | ctnursenav@kumc.edu |
| Phone: | 913-945-7552 |
A Phase I/II Study of Palbociclib, Letrozole and T-DM1 in Trastuzumab Refractory Estrogen Receptor Positive (ER+) and HER2 Positive Metastatic Breast Cancer
This study will determine the recommend dose of palbociclib in combination with letrozole and
another medication, Ado-trastuzumab emtansine (T-DM1). Additionally, researchers will
determine how well this recommended dose will improve outcomes in this type of advanced
breast cancer.
The study will include a safety lead-in with escalating dosing of palbociclib to determine
the recommended phase II dose (RP2D) of palbociclib in this combination and an expanded phase
II of palbociclib at the RP2D in combination with letrozole and Ado- trastuzumab Emtansine
(T-DM1).
The starting dose of palbociclib will be 75 milligrams (mg) by mouth (PO) daily for each 21
day cycle. If 0 of 3 patients at the 75mg dose level experience a dose limiting toxicity
(DLT), the next 3 patients will be enrolled at the next higher dosing cohort of 100mg PO
daily for each 21 day cycle. If 0 of 3 patients at the 100mg dose level experience a DLT, the
next 3 patients will be enrolled at the next higher dosing cohort of 125mg PO daily for each
21 day cycle. If 0 of 3 patients at the 125mg dose level experience a DLT, 125mg PO daily of
palbociclib will be the phase II recommended dose used in the phase II expanded cohort.
Patients receiving the phase II recommended dose in phase I will be enrolled in phase II of
the study.
During safety lead-in and expanded phase II, Letrozole 2.5mg PO will be administered daily
for each 21 day cycle and T-DM1 3.6 milligrams per kilograms intravenously (IV) will be
administered on Day 1 of each 21 day cycle.
another medication, Ado-trastuzumab emtansine (T-DM1). Additionally, researchers will
determine how well this recommended dose will improve outcomes in this type of advanced
breast cancer.
The study will include a safety lead-in with escalating dosing of palbociclib to determine
the recommended phase II dose (RP2D) of palbociclib in this combination and an expanded phase
II of palbociclib at the RP2D in combination with letrozole and Ado- trastuzumab Emtansine
(T-DM1).
The starting dose of palbociclib will be 75 milligrams (mg) by mouth (PO) daily for each 21
day cycle. If 0 of 3 patients at the 75mg dose level experience a dose limiting toxicity
(DLT), the next 3 patients will be enrolled at the next higher dosing cohort of 100mg PO
daily for each 21 day cycle. If 0 of 3 patients at the 100mg dose level experience a DLT, the
next 3 patients will be enrolled at the next higher dosing cohort of 125mg PO daily for each
21 day cycle. If 0 of 3 patients at the 125mg dose level experience a DLT, 125mg PO daily of
palbociclib will be the phase II recommended dose used in the phase II expanded cohort.
Patients receiving the phase II recommended dose in phase I will be enrolled in phase II of
the study.
During safety lead-in and expanded phase II, Letrozole 2.5mg PO will be administered daily
for each 21 day cycle and T-DM1 3.6 milligrams per kilograms intravenously (IV) will be
administered on Day 1 of each 21 day cycle.
Inclusion Criteria:
- Pathologically confirmed diagnosis of Estrogen Receptor (ER) positive and HER2 (human
epidermal growth factor receptor 2) positive metastatic breast cancer based on local
laboratory results.
- Prior treatment with a taxane (including paclitaxel, docetaxel and/or nanoparticle
protein-bound paclitaxel).
- Prior treatment with trastuzumab with or without pertuzumab.
- Measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors
(RECIST) criteria version 1.1.
- Eastern Cooperative Oncology Group Performance Status of 0-2
- Adequate organ and marrow function
- Women must be post-menopausal
- Must be able to swallow pills
Exclusion Criteria:
- Current or anticipated use of other investigational agents
- Prior therapy with a cyclin-dependent kinase 4/6 inhibitor
- Subject has received chemotherapy or radiotherapy within 14 days prior to Cycle 1, Day
1 of the study or has not recovered from adverse events due to agents administered
more than 14 days earlier
- Subject has leptomeningeal disease
- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to palbociclib or other agents used in study
- Subject has other illness or disease that the investigator believes will interfere
with study requirements.
We found this trial at
5
sites
8919 Parallel Parkway
Kansas City, Kansas 66112
Kansas City, Kansas 66112
Phone: 913-945-7552
Click here to add this to my saved trials
2650 Shawnee Mission Parkway
Kansas City, Kansas 66205
Kansas City, Kansas 66205
Phone: 913-945-7552
Click here to add this to my saved trials
8700 North Green Hills Road
Kansas City, Missouri 64154
Kansas City, Missouri 64154
Phone: 913-945-7552
Click here to add this to my saved trials
4881 Northeast Goodview Circle
Lee's Summit, Missouri 64064
Lee's Summit, Missouri 64064
Phone: 913-945-7552
Click here to add this to my saved trials
12200 West 110th Street
Overland Park, Kansas 66210
Overland Park, Kansas 66210
Phone: 913-945-7552
Click here to add this to my saved trials